CAR T Cell Therapy Targets Rogue Antibodies in Stiff Person Syndrome, Improving Walking Speed in Patients Like Celine Dion

When news broke about an experimental drug showing promise for stiff person syndrome—a rare neurological disorder that’s affected global icon Celine Dion for years—it didn’t just make headlines in neurology journals. For residents of Chicago managing their own neurological health journeys, or supporting loved ones through similar diagnoses, this development from the American Academy of Neurology’s annual meeting hits close to home. The therapy, called miv-cel and developed by Kyverna Therapeutics, represents more than just another clinical trial; it signals a potential shift in how we approach autoimmune neurological conditions that have long resisted conventional treatment.

What makes this development particularly significant for Chicagoans is the direct connection to local expertise driving the research. Dr. Amanda Piquet, the neurologist who presented the findings at the April 21 conference in Chicago, serves as an Associate Professor of Neurology at the University of Colorado Anschutz Medical Campus—but her work is deeply intertwined with the city’s medical community through her role as Director of the Autoimmune Neurology Program. This isn’t abstract science happening far away; it’s research shaped by physicians who regularly consult with Chicago-based specialists at institutions like Northwestern Memorial Hospital and Rush University Medical Center, where patients with complex neurological conditions often seek second opinions or enroll in advanced trials.

The science behind miv-cel builds on years of frustration with existing options. As Dr. Piquet noted in her presentation, current therapies for stiff person syndrome—like immunomodulators or symptom-managing drugs—offer limited relief and often lose effectiveness over time, leaving many patients dependent on mobility aids. But this CAR T cell approach takes a different strategy: instead of merely suppressing symptoms, it engineers a patient’s own immune cells to target and eliminate the rogue antibodies attacking the nervous system. In the trial, participants reported meaningful improvements in walking speed, reduced stiffness, and lower disability scores after just a single infusion—outcomes Dr. Piquet described as “unprecedented” in both magnitude and consistency.

For Chicago’s neurological community, this arrives at a pivotal moment. The city has long been a hub for autoimmune research, with the Rehabilitation Institute of Chicago (now Shirley Ryan AbilityLab) pioneering neurorehabilitation techniques for decades. Meanwhile, organizations like the Chicago Chapter of the National Multiple Sclerosis Society regularly host educational forums where patients discuss emerging therapies—conversations that now increasingly include discussions about cellular treatments like miv-cel. What’s especially relevant is how this therapy might intersect with Chicago’s unique healthcare landscape: the city’s extensive public transit system means improved mobility isn’t just about personal independence—it affects access to jobs, healthcare appointments, and community resources across neighborhoods from the Loop to Englewood.

Looking beyond the immediate findings, this development touches on broader trends in neuroimmunology. Scientists have observed rising interest in repurposing cancer-fighting immunotherapies for autoimmune conditions—a shift reflected in growing clinical trial activity at centers like the University of Chicago Medicine’s Comprehensive Cancer Center. If miv-cel gains FDA approval, it could pave the way for similar approaches targeting other antibody-mediated disorders that affect Chicago residents, from certain forms of encephalitis to treatment-resistant myasthenia gravis. The socioeconomic implications are equally noteworthy: reducing long-term disability could lessen burdens on Illinois’ Medicaid system and decrease lost productivity costs estimated in the billions nationally for chronic neurological conditions.

Given my background in translating complex medical advances into actionable community insights, if this trend impacts you or someone you know in Chicago, here are three types of local professionals worth connecting with:

• Neuroimmunology Specialists: Glance for neurologists with specific training in autoimmune conditions who participate in clinical research—many affiliated with academic medical centers like Northwestern or Rush offer access to emerging trials while maintaining rigorous safety protocols. Key credentials include fellowship training in neuroimmunology and active involvement with organizations like the American Autoimmune Related Diseases Association.

• Neurorehabilitation Therapists: Seek licensed physical or occupational therapists experienced in neurological conditions who understand how to maximize gains from new therapies. The best providers will customize exercises around your specific symptom patterns—whether that means gait training for improved walking or spasticity management techniques—and often collaborate directly with prescribing neurologists to adjust rehab plans as treatment progresses.

• Patient Navigation Coordinators: These professionals—often found through hospital patient services departments or nonprofits like the Chicago Health Outreach—help manage the logistical and emotional complexities of accessing advanced therapies. They can assist with insurance prior authorizations, coordinate travel for infusions at specialized centers, and connect you with support groups where others share real-world experiences with cellular therapies.

Ready to find trusted professionals? Browse our complete directory of top-rated health & medicine experts in the Chicago area today.